NO941986L - Anti-kreft immunoterapeutisk vektorkonstruksjoner - Google Patents

Anti-kreft immunoterapeutisk vektorkonstruksjoner

Info

Publication number
NO941986L
NO941986L NO941986A NO941986A NO941986L NO 941986 L NO941986 L NO 941986L NO 941986 A NO941986 A NO 941986A NO 941986 A NO941986 A NO 941986A NO 941986 L NO941986 L NO 941986L
Authority
NO
Norway
Prior art keywords
altered
expression
vector constructs
recombinant virus
altered cellular
Prior art date
Application number
NO941986A
Other languages
English (en)
Other versions
NO941986D0 (no
Inventor
Sunil Chada
Mordechai Bodner
Douglas J Jolly
Jack R Barber
Caty E Dejesus
Original Assignee
Viagene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viagene Inc filed Critical Viagene Inc
Publication of NO941986D0 publication Critical patent/NO941986D0/no
Publication of NO941986L publication Critical patent/NO941986L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer en fremgangsmåte for å ødelegge selekterte tumorceller, som omfatter at det til et varmblodig dyr administreres en vektorkonstruksjon som styrer ekspresjonen av minst en immunogen, ikke-tumorogen form av en endret cellulær komponent som normalt er assosiert med de selekterte tumorceller. Det tilveiebringes også vektor- konstruksjoner som styrer ekspresjonen av endrede cellulære komponenter. Representative endrede cellulære komponenter innbefatter ras', p53", Kb", endret protein som kodes av Wilms tumorgenet, ubikvitin", DCC, APC, MCC, neu, en endret reseptor og bcr/abl. Det tilveiebringes også rekombinante virus som er bærere av en vektorkonstruksjon, målceller infisert med det rekombinante virus og farmasøytiske preparater som omfatter det rekombinante virus og et farmasøytisk akseptabelt bærer- eller fortynningsmiddel.
NO941986A 1991-11-29 1994-05-27 Anti-kreft immunoterapeutisk vektorkonstruksjoner NO941986L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80032891A 1991-11-29 1991-11-29
PCT/US1992/010309 WO1993010814A1 (en) 1991-11-29 1992-11-30 Anti-cancer immunotherapeutic vector constructs

Publications (2)

Publication Number Publication Date
NO941986D0 NO941986D0 (no) 1994-05-27
NO941986L true NO941986L (no) 1994-07-27

Family

ID=25178122

Family Applications (1)

Application Number Title Priority Date Filing Date
NO941986A NO941986L (no) 1991-11-29 1994-05-27 Anti-kreft immunoterapeutisk vektorkonstruksjoner

Country Status (10)

Country Link
US (1) US5693522A (no)
EP (1) EP0615453B1 (no)
JP (1) JPH07501942A (no)
AT (1) ATE152915T1 (no)
AU (1) AU671971B2 (no)
CA (1) CA2117303C (no)
DE (1) DE69219787T2 (no)
FI (1) FI942503A0 (no)
NO (1) NO941986L (no)
WO (1) WO1993010814A1 (no)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662896A (en) * 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
ATE261314T1 (de) * 1992-07-22 2004-03-15 Univ Princeton P53 impfstoff
US20030086935A1 (en) * 1992-07-22 2003-05-08 Levine Arnold J. p53 vaccine
AU676204B2 (en) 1992-09-18 1997-03-06 Canji, Inc. Gene therapy by retroviral vector with tumor suppressive gene
US6953573B1 (en) 1993-03-17 2005-10-11 University Of Washington Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US5700657A (en) * 1993-12-13 1997-12-23 Genzyme Corporation Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby
US5629192A (en) * 1994-02-04 1997-05-13 The United States Of America As Represented By The Department Of Health And Human Services ETS1 gene: a human tumor suppressor gene
KR970702915A (ko) * 1994-04-29 1997-06-10 린다 버겐 종양 세포의 치료 감응성 향상 방법(Enhancing The Sensitivity of Tumor Cells to Therapies)
ATE381624T1 (de) 1994-05-09 2008-01-15 Oxford Biomedica Ltd Retrovirale vektoren mit verminderter rekombinationsrate
ATE399022T1 (de) * 1995-10-20 2008-07-15 Univ Nebraska Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen
EP0871747A1 (en) * 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation mediated by gene-modified dendritic cells
US6365151B1 (en) * 1996-01-19 2002-04-02 Philadelphia Health And Educational Corporation Cellular immunogens comprising cognate proto-oxogenes
US6942862B2 (en) * 1996-04-01 2005-09-13 University Of Washington Methods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins
EP0907746B1 (en) 1996-04-05 2008-02-20 Novartis Vaccines and Diagnostics, Inc. Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
JP2001500738A (ja) * 1996-09-17 2001-01-23 カイロン コーポレイション 細胞内疾患を処置するための組成物および方法
US20040202680A1 (en) * 1997-01-30 2004-10-14 O'hagan Derek Microparticles with adsorbent surfaces, methods of making same, and uses thereof
DK0991403T3 (da) * 1997-01-30 2003-07-28 Chiron Corp Anvendelse af mikropartikler med adsorberet antigen til stimulering af immunresponser
US6884435B1 (en) * 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
EP0984813A1 (en) 1997-05-13 2000-03-15 Stuart D. Edwards Global medical treatment method and apparatus
FR2775601B1 (fr) * 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) * 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7144581B2 (en) * 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) * 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030039635A1 (en) * 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
EP1123086B1 (en) 1998-10-20 2010-03-03 Androclus Technologies S.r.l. in liquidazione Artificial antigen-specific cells and related methods
US6787154B2 (en) * 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
US7807377B2 (en) 1998-10-20 2010-10-05 Salvatore Albani Method of isolating antigen-specific T cells employing artificial antigen presenting cells
GB9907414D0 (en) 1999-03-31 1999-05-26 Cancer Res Campaign Tech Improvements relating to prodrugs
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
AU5003200A (en) 1999-05-14 2000-12-05 United States Of America As Represented By The Department Of Veterans Affairs, The Isolation and characterization of epidermal growth factor related protein
US7049410B2 (en) * 1999-05-14 2006-05-23 Majumdar Adhip P N Antibodies to a novel EGF-receptor related protein (ERRP)
WO2001016167A2 (en) * 1999-09-01 2001-03-08 The Johns Hopkins University Beta-catenin, tcf-4, and apc interact to prevent cancer
US9289487B2 (en) * 1999-09-14 2016-03-22 Antigen Express, Inc. II-key/antigenic epitope hybrid peptide vaccines
US20030235594A1 (en) * 1999-09-14 2003-12-25 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
US6432409B1 (en) 1999-09-14 2002-08-13 Antigen Express, Inc. Hybrid peptides modulate the immune response
US6656718B2 (en) 2000-07-07 2003-12-02 Cancer Research Technology Limited Modified carboxypeptidase enzymes and their use
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
EP1356048A2 (en) 2000-12-04 2003-10-29 Argonex Pharmaceuticals Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
EP2305299B1 (en) 2001-05-31 2017-03-01 GlaxoSmithKline Biologicals SA Chimeric alphavirus replicon particles
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US7179645B2 (en) * 2002-09-24 2007-02-20 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
EP1556072B1 (en) 2002-09-17 2010-05-19 Antigen Express, Inc. Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES
WO2005087260A1 (en) * 2004-03-04 2005-09-22 Corixa Corporation Co-encapsulated wt1 polypeptide and immunostimulant microsphere formulations and methods thereof
JP2008504292A (ja) 2004-06-24 2008-02-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 免疫増強用の化合物
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
JP2009511636A (ja) 2005-10-18 2009-03-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド アルファウイルスレプリコン粒子による粘膜免疫および全身免疫
CA2646539A1 (en) * 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
CA2647100A1 (en) * 2006-03-23 2007-09-27 Novartis Ag Methods for the preparation of imidazole-containing compounds
US8063063B2 (en) * 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
CA2999337C (en) * 2008-01-28 2023-03-07 Implantica Patent Ltd. An implantable drainage device
CA2750922A1 (en) * 2009-01-28 2010-08-05 Antigen Express, Inc. Li-key hybrid peptides that modulate the immune response to influenza
CN102933267B (zh) 2010-05-28 2015-05-27 泰特里斯在线公司 交互式混合异步计算机游戏基础结构
CA2954892A1 (en) 2016-01-19 2017-07-19 Pfizer Inc. Immunogens derived from tumor-associated antigens or nucleic acid molecules encoding the immunogens

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405712A (en) * 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4965196A (en) * 1983-01-19 1990-10-23 Genentech, Inc. Polycistronic expression vector construction
GB8424757D0 (en) * 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4871838A (en) * 1985-07-23 1989-10-03 The Board Of Rijks Universiteit Leiden Probes and methods for detecting activated ras oncogenes
US4931275A (en) * 1985-12-02 1990-06-05 Yeda Research & Development Co., Ltd. Anti-tumor vaccines and their preparation
CA1310924C (en) * 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
US4861719A (en) * 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4980289A (en) * 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
DE3854313D1 (de) * 1987-05-29 1995-09-21 Dana Farber Cancer Inst Inc Cis-Wirkung-Repressionen-Sequenzen, Cis-Wirkung-Antirepressionen-Sequenzen, Vektoren, Verfahren zur Vorbereitung und Anwendung.
WO1989001973A2 (en) * 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
JP3015383B2 (ja) * 1987-09-11 2000-03-06 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 形質導入した線維芽およびそれらの使用
WO1989005349A1 (en) * 1987-12-09 1989-06-15 The Australian National University Method of combating viral infections
US4957859A (en) * 1988-02-16 1990-09-18 Hoffmann-La Roche Inc. Antibodies for transforming ras protein
CA1339354C (en) * 1988-09-01 1997-08-26 The Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
WO1990011092A1 (en) * 1989-03-21 1990-10-04 Vical, Inc. Expression of exogenous polynucleotide sequences in a vertebrate
CA2055441C (en) * 1989-05-19 2003-01-07 Robert M. Hudziak Her2 extracellular domain
FR2668064B1 (fr) * 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.

Also Published As

Publication number Publication date
EP0615453A1 (en) 1994-09-21
WO1993010814A1 (en) 1993-06-10
JPH07501942A (ja) 1995-03-02
FI942503A (fi) 1994-05-27
FI942503A0 (fi) 1994-05-27
AU3229793A (en) 1993-06-28
ATE152915T1 (de) 1997-05-15
EP0615453B1 (en) 1997-05-14
AU671971B2 (en) 1996-09-19
US5693522A (en) 1997-12-02
CA2117303A1 (en) 1993-06-10
CA2117303C (en) 2000-10-17
NO941986D0 (no) 1994-05-27
DE69219787T2 (de) 1997-08-28
DE69219787D1 (de) 1997-06-19

Similar Documents

Publication Publication Date Title
NO941986L (no) Anti-kreft immunoterapeutisk vektorkonstruksjoner
WO1991002805A3 (en) Recombinant retroviruses delivering vector constructs to target cells
IL89701A0 (en) Recombinant retroviruses,method for the production thereof and pharmaceutical composition containing the same
DK0526905T3 (da) Multimerer af TNF-receptorers oplöselige former, deres fremstilling og farmaceutiske præparater indeholdende dem
DK653688D0 (da) Stabiliserede laegemiddelaktive forbindelser, fremgangsmaade til deres frmstilling samt stabile laegemiddelpraeparater
DK551989D0 (da) 3-piperidinyl-1,2-benzisoxazoler, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende samme
DK0642581T3 (da) Clostridium perfringens-vacciner
BR9401183A (pt) Composto e formulação farmacêutica
CY1113421T1 (el) Πυρηνικα οξεα και πολυπεπτιδια υποδοχεα
KR860005636A (ko) 활성성분으로 스페르구알린(Spergualin)을 함유하는 주사제 조성물과 그 제조방법.
DK1149910T3 (da) Farmaceutisk præparat til behandling af papillomavirustumorer og -infektion
DK1089968T3 (da) Thyroideahormonanaloger og fremgangsmåder til deres fremstilling
DE69420872D1 (de) Hgh enthaltende pharmazeutische zubereitungen
AU4826493A (en) Anti-feline immunodeficiency virus (fiv) vaccines
NO178261C (no) Substituerte diaminoftalimider og analoger, farmasöytiske preparater inneholdende dem samt deres anvendelse i medikamenter
AU597090B2 (en) 2-acyloxypropylamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
WO2000052045A3 (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
DE69431662D1 (de) Stabilisierte tablettenformulierung
DK598184A (da) 3-aryl-1,2-benzisoxazolsulfonyl- og -sulfinylalkansyrer og farmaceutisk acceptable salte deraf, deres fremstilling og anvendelse som laegemidler
IT1255678B (it) Composizioni farmaceutiche per la somministrazione di paratormone, suoi frammenti biologicamente attivi o peptidi correlati per via rettale.
DE69632205T2 (de) Herstellung von bacillus thuringiensis integrants